Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 26 March 2013
Vol. 6, Issue 268, p. eg3
[DOI: 10.1126/scisignal.2004149]

EDITORIAL GUIDES

Focus Issue: From Genomic Mutations to Oncogenic Pathways

Nancy R. Gough1*

1 Editor of Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005, USA.

Abstract: This two-issue series focuses on how understanding how signaling pathways are altered in cancer cells can enable researchers to develop more effective therapies. Cancer is a pleiotropic disease. Tumor cells change over time and, even within a specific tumor, cells may have different mutations and dependencies on different signaling pathways for survival or for metastatic potential. New tools and technologies for genomic- or systems-level analysis, as well as conventional biochemistry and cell biology approaches, are revealing how signaling pathways contribute to cancer development, cancer evolution, and drug resistance.

* Corresponding author. E-mail: ngough{at}aaas.org

Citation: N. R. Gough, Focus Issue: From Genomic Mutations to Oncogenic Pathways. Sci. Signal. 6, eg3 (2013).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882